Why BioGaia stock moves
BioGaia rose clearly while the market fell clearly.
Written after the close on ·
Why today
16,292 news analyzed todayBioGaia rose clearly while the market fell clearly.
No company news from that session explains the move.
Over the last five trading days the shares rose slightly, while OMX Stockholm 30 was roughly flat.
The insider share sale by the vice chairman, David Dangoor, was reported on Wednesday last week, but it is only background and not a cause of the move.
Trading volume was well below its usual level, so the move came on thin trading.
Today's move of +1.24% was 1.4 times a normal day's 0.9%. OMX Stockholm 30 moved −1.01% on the same day.
BioGaia +1.24%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for BioGaia.
BioGaia earned more than expected in 4 out of 6 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 5 out of 6 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 122.10 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 1.21 SEK (February 12). For the current fiscal year, expected earnings per share changed from 3.83 SEK three months ago to 4.05 SEK now. 2026 estimate: 4.05 SEK. 2027 estimate: 4.86 SEK. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. October 26: Sell about 19 m SEK. February 13: Buy about 58 thousand SEK. December 23: Buy about 40 thousand SEK. December 5: Buy about 490 thousand SEK. December 5: Buy about 195 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −5% and earnings per share −5%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 12.4 bn SEKRevenue 2025: 1.5 bn SEK
What the key figures say about BioGaia
The figures connect what BioGaia earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: 3.29 SEK–3.70 SEK. Peers: Hims & Hers Health -$0.64, Lundbeck 3.92 DKK. 2026 estimate: 4.05 SEK (3.85 SEK–4.26 SEK). 2027 estimate: 4.86 SEK (4.78 SEK–4.94 SEK).
What the company sold during the year.
2022–2025: 1.1 bn SEK–1.5 bn SEK. Peers: Alvotech $495M, Hims & Hers Health $2.6B, Lundbeck 26.0 bn DKK. 2026 estimate: 1.7 bn SEK (1.7 bn SEK–1.7 bn SEK). 2027 estimate: 1.9 bn SEK (1.9 bn SEK–2.0 bn SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: 28.8%–34.0%. Peers: Alvotech 9.7%, Hims & Hers Health −6.0%, Lundbeck 21.8%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: 18.0%–25.3%. Peers: Hims & Hers Health −32.0%, Lundbeck 15.4%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 22.6–32.3. Peers: Lundbeck 14.3. 2026 estimate: 30.1. 2027 estimate: 25.1.
What investors pay for each unit the company sells.
2022–2025: 6.98–7.96. Peers: Hims & Hers Health 2.35, Lundbeck 2.14. 2026 estimate: 7.31. 2027 estimate: 6.46.
Money paid to shareholders per share, summed by calendar year.
2017–2025: 0.68 SEK–6.90 SEK.
The ordinary yearly dividend as a percentage of the share price. In the past 12 months, the company paid 4.00 SEK per share, 3.3% of the share price.
2022–2025: 2.9%–6.5%. Peers: Hims & Hers Health 0.0%, Lundbeck 2.0%.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 4.28–8.17. Peers: Hims & Hers Health 18.72, Lundbeck 2.06.
Cash left after investments, divided by the number of shares.
2022–2025: 2.98 SEK–3.74 SEK. Peers: Alvotech -$0.94, Hims & Hers Health $0.26, Lundbeck 5.20 DKK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 82.3%–89.1%.
The dividend explained
A dividend is money paid to shareholders. BioGaia paid 4.00 SEK per share in the twelve months through November 6, 2026.
On the ex-dividend day, May 8, 2026, BioGaia traded without the right to the 4.00 SEK dividend. The price went from 130.60 SEK to 128.80 SEK; including the dividend, the day's change was +1.7%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2017: 1.50 SEK2018: 1.80 SEK2019: 2.00 SEK2020: 0.75 SEK2021: 0.68 SEK2022: 2.98 SEK2023: 2.90 SEK2024: 6.90 SEK2025: 6.90 SEK2026 so far: 4.00 SEK
What to watch next, and why
The earnings report shows how BioGaia's revenue and profit have changed.
- Earnings report
The earnings report shows how BioGaia's revenue and profit have changed.
Add to calendar
More about BioGaia
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- David Dangoor, board memberSellabout 19 m SEK
- Outi Armstrong, board memberBuyabout 58 thousand SEK
- Caroline Mofors, senior executiveBuyabout 40 thousand SEK
- Anthon Jahreskog, board memberBuyabout 490 thousand SEK
- Alexander Kotsinas, CFOBuyabout 195 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days BioGaia usually moved about 4.1%. On a normal day it moves 0.9%.
+4.27% Why? +7.59% +8.74% −6.75%
10,000 SEK in BioGaia bought on November 7, 2016 is worth 29,500 SEK today, with dividends reinvested.
What would 10,000 SEK in BioGaia be worth today? →
What would 10,000 SEK in BioGaia be worth today?
29,500 SEK
with dividends reinvested, bought on November 7, 2016.
The five biggest days of the journey
· −17.4% · the whole market fell 1.2% the same day
· +16.6% · the whole market fell 0.4% the same day · report day
· +16.0% · the whole market rose 2.1% the same day
· +13.4% · the whole market rose 1.1% the same day · report day
· +12.4% · the whole market rose 4.5% the same day
Earlier days
+1.41% market −0.11% BioGaia rose slightly over the trading week while the OMX Stockholm 30 index was roughly flat. Read →
BioGaia rose slightly over the trading week while the OMX Stockholm 30 index was roughly flat.
The shares rose clearly in the last session, moving against a market that fell clearly that day.
Company news this week was mostly routine: a clinical study on infant colic and a study on Protectis Plus BABY.
Trading was thin, so price moves may be less reliable.
−1.07% market −0.32% BioGaia fell that day, while OMX Stockholm 30 slipped slightly. Read →
BioGaia fell that day, while OMX Stockholm 30 slipped slightly.
No company news explains the drop, so the cause is unclear.
Over the last five trading days the shares were roughly unchanged, a little behind a slightly rising market.
The shares sit well above their early December low but below their mid-May high.
+2.44% market +0.83% BioGaia rose, moving well ahead of the market. Read →
BioGaia rose, moving well ahead of the market.
The most likely reason is the new clinical study showing its Protectis Plus BABY product reduces infant colic (crying and distress) after seven days.
The stock also traded about twice its usual volume.
Over the last five trading days, BioGaia was roughly unchanged, while OMX Stockholm 30 rose slightly.
Insider share sales by the vice chairman were reported earlier and are background only.
−5.42% market +3.01% BioGaia fell sharply over the week, a big move for the stock and against a clearly rising OMX Stockholm 30. Read →
BioGaia fell sharply over the week, a big move for the stock and against a clearly rising OMX Stockholm 30.
The main news was the strong third-quarter report on 22 October, before this window, with sales and profit both up sharply.
In the window, Vice Chairman David Dangoor sold shares worth about SEK 19 million on 26 October, which likely added pressure.
Trading was thin in the last session, and the share is still well above its December low.
−1.24% market +0.41% BioGaia fell yesterday, against a slightly rising market. Read →
BioGaia fell yesterday, against a slightly rising market.
Over five days BioGaia fell very sharply, while OMX Stockholm 30 rose sharply.
A board member's large share sale yesterday is the company news most likely linked to the drop.
David Dangoor, a board member, sold about 150 thousand shares, worth about 19 million SEK.
A sale can have many reasons and is no view on the shares.
−1.94% market +0.33% BioGaia fell sharply, against a slightly rising market. Read →
BioGaia fell sharply, against a slightly rising market.
It fell clearly over the last five trading days, while OMX Stockholm 30 rose slightly.
Trading was about twice its normal level, which makes the drop more notable.
−2.20% market +1.57% BioGaia fell sharply without a company-news explanation. Read →
BioGaia fell sharply without a company-news explanation.
Over the last five trading days, BioGaia was roughly unchanged and moved less than the market, which slipped slightly.
In the last session the market rose clearly while BioGaia went the other way, and trading was about three times its usual level.
The Q3 2026 results, published last week before that session, beat expectations, with operating profit up 54 percent, so that news was already known and does not explain the drop.
Analysts raised their price targets, the prices they see as fair, after the report, with some holding or downgrading their rating.
−1.55% market +0.41% BioGaia fell after SB1 Markets cut its rating to neutral, a downgrade from buy, on Thursday. Read →
BioGaia fell after SB1 Markets cut its rating to neutral, a downgrade from buy, on Thursday.
Over the same session, OMX Stockholm 30 rose slightly, so BioGaia moved against the market.
That day's trading was heavy, around five times a normal session, which points to a move that many investors reacted to.
The stock still rose clearly over the last five trading days, while the market fell sharply, so the week went the other way.
Earlier, strong third-quarter results lifted sentiment, with operating profit up 54 percent and earnings per share at SEK 1.09 (0.65), which likely supported the rise.
+2.74% market −3.67% BioGaia rose clearly over the last five trading days, while the OMX Stockholm 30 fell sharply, so the shares moved against the market. Read →
BioGaia rose clearly over the last five trading days, while the OMX Stockholm 30 fell sharply, so the shares moved against the market.
The main driver was the strong third-quarter report published yesterday, with operating profit up 54% and earnings beating expectations.
Several analysts raised their price targets, the share price they see as fair, after the report.
Trading volume was far above normal, about four times a typical session, which shows heavy interest.
+4.27% market −2.51% BioGaia rose sharply after its strong third-quarter report, published that day. Read →
BioGaia rose sharply after its strong third-quarter report, published that day.
The stock moved against the market, which fell clearly over the same days, so the rise was company-specific.
Operating profit rose 54 percent, and the operating margin (profit as a share of sales) widened to 33 percent from 26 percent.
Earnings per share, the profit per share, came in at 1.09 against 0.65, beating expectations.
Over the last five trading days, the stock rose sharply, a big move for BioGaia and roughly twice a normal five-day stretch.
Learn more · Why do stocks go up and down?